Abstract
Late-onset (≥50 years) relapsing remitting Multiple Sclerosis (LORRMS) is associated with adverse prognosis but established marker(s) of such poor prognosis are still lacking in the clinical practice. The aim of the study is to compare effectiveness of injectable and oral first line disease modifying therapies (DMTs) in a cohort of patients with LORRMS for time to first relapse, time to confirmed disability progression (CDP), and, additionally, for time to discontinuation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
